Pediatric Bill Toll-Free Adverse Event Hotline Is Of Concern To Pharmacy
Executive Summary
The retail pharmacy trade associations are urging the House leadership to delete language creating an adverse event reporting hotline from the pediatric exclusivity bill
You may also be interested in...
Pediatric Prozac Phase IV Commitments Will Test Exclusivity Incentive
Lilly's Phase IV commitments for additional research on pediatric use of Prozac will serve as a high-profile test of FDA's pediatric exclusivity incentive
Pediatric Prozac Phase IV Commitments Will Test Exclusivity Incentive
Lilly's Phase IV commitments for additional research on pediatric use of Prozac will serve as a high-profile test of FDA's pediatric exclusivity incentive
House Pediatric Exclusivity Bill Passes; CBO Scoring Flawed, Tauzin Says
Thirty to 50 pediatric studies of generic drugs would be funded by the National Institutes of Health over the next five years under HR 2887, House Energy & Commerce Committee Chairman Billy Tauzin (R-La.) estimated